Publications
5891 Results
- Journal / Conference
- Journal of Clinical Oncology 32:5s (suppl; abstr LBA3); ASCO Annual Meeting (May 30-June 3, 2014, Chicago, IL), scientific plenary session (oral);
- Year
- 2014
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/C80405
CALGB/SWOG 80405: PHASE III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (uMCRC).
- Journal / Conference
- Journal of Clinical Oncology 32:5s (suppl; abstr 6617); ASCO Annual Meeting (May 30-June 3, 2014, Chicago, IL), general poster session;
- Year
- 2014
- Research Committee(s)
- Leukemia
- Study Number(s)
- S1117
NCI pilot intervention program to assist accrual for challenging late phase clinical trials
- Journal / Conference
- Journal of Clinical Oncology 32:5s (suppl; abstr LBA2); ASCO Annual Meeting (May 30-June 3, 2014, Chicago, IL), scientific plenary session (oral);
- Year
- 2014
- Research Committee(s)
- Genitourinary
- Study Number(s)
- CTSU/E3805
Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial
- Journal / Conference
- Journal of Clinical Oncology 32:5s (suppl; abstr LBA1); ASCO Annual Meeting (May 30-June 3, 2014, Chicago, IL), LBA scientific plenary session (oral);
- Year
- 2014
- Research Committee(s)
- Breast and Cancer Survivorship
Randomized comparison of adjuvant treatment with aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) versus tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) breast cancer (BC): joint analysis of TEXT and SOFT
- Journal / Conference
- International Society for Quality of Life Research annual meeting (Berlin, Germany, Oct. 15-18, 2014); oral presentation;
- Year
- 2014
- Research Committee(s)
- Cancer Control, Prevention, Screening, and and Surveillance
- Study Number(s)
- S0000, SWOG-9217
Health-related quality of life outcomes in prostate cancer prevention clinical trials
- Journal / Conference
- Urology 84(1):127-131;
- Year
- 2014
- Research Committee(s)
- Cancer Control
- PMID
- PMID24824408
- PMC
- PMC4077907
- Study Number(s)
- SWOG-9217
Androgen receptor CAG repeat length and TMPRSS2:ETS prostate cancer risk: results from the Prostate Cancer Prevention Trial
- Journal / Conference
- Nature Genetics 46(9):994-1000;
- Year
- 2014
- Research Committee(s)
- Prevention, Screening, and and Surveillance
- PMID
- PMID25086665
- PMC
- PMC4191666
- Study Number(s)
- S0000
Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer
- Journal / Conference
- Cancer 120(21):3329-3337;
- Year
- 2014
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID25041994
- PMC
- PMC4259283
- Study Number(s)
- SWOG-9304 (INT-0144)
Polymorphisms in folate-metabolizing enzymes and response to 5-fluorouracil among stage II or III rectal cancer patients (INT-0144; SWOG 9304)
- Journal / Conference
- Journal of Clinical Oncology, 32(22):2311-2317; accepted 2/27/14
- Year
- 2014
- Research Committee(s)
- Breast
- PMID
- PMID24934787
- PMC
- PMC4105484
Comparison of doxorubicin and cyclophosphamide (AC) versus single agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0-3 positive axillary nodes: CALGB 40101 (Alliance)
- Journal / Conference
- Journal of Clinical Oncology 32(31):3483-3489;
- Year
- 2014
- Research Committee(s)
- Breast
- PMID
- PMID24888818
- PMC
- PMC4209100
- Study Number(s)
- S0500